To achieve $300 Mil. 2012, Dec. 4th Quarter will be a whopper $100 Million. This can only mean that Zevalin sales locked up and still in the Bayer accounts will be released attributable to SPPI 4th Quarter.
It depends on how Folotyn sales for 2012 will be accounted for.
LOL. Look at the 10Q filing for 30/9.
Pro forma revenue at 30/9 is 229 mio. $
That means Q4 will be minimum 71 mio. $. Up from 69 this Q
Your 100 mio. $ is patetic.
we still dont know what is going forward run rate in terms of expense post-allos acquisition
i believe they reported allos only month of september in Q3